Sushil K. Badrising

Statistics

Publications

Citations

223

H-Index

Active since

2013

Affiliations

The Netherlands Cancer Institute(Current)

Isala

Sint Franciscus Gasthuis

Tergooi

Oncode Institute

Sushil K. Badrising is an author at The Netherlands Cancer Institute specializing in oncology, medicine, and metastatic castration-resistant prostate cancer.

ORCID

Publications per year

2013–2023

Publications

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

Sushil K. Badrising, Vincent van der Noort, Inge M. van Oort et al. · Cancer · 2013 · 135 citations

Medicine, Oncology, Pharmacology +16

A prospective observational registry evaluating clinical outcomes of Radium‐223 treatment in a nonstudy population

Sushil K. Badrising, Rebecca D. Louhanepessy, Vincent van der Noort et al. · International Journal of Cancer · 2019 · 31 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study

C. Steendam, Sophie M. Ernst, Sushil K. Badrising et al. · Lung Cancer · 2023 · 18 citations · Full text

Medicine, Oncology, Pharmacology +16

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223

Sushil K. Badrising, Rebecca D. Louhanepessy, Vincent van der Noort et al. · Prostate Cancer and Prostatic Diseases · 2021 · 14 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

Sushil K. Badrising, Vincent van der Noort, Paul Hamberg et al. · Oncology · 2016 · 13 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

1–5 of 6